Blood Res.  2017 Dec;52(4):311-315. 10.5045/br.2017.52.4.311.

Human parvovirus B19 and parvovirus 4 among Iranian patients with hemophilia

• Javanmard
• Ziaee M
• Ghaffari H
• Namaei MH
• Tavakoli A
• Mollaei H
• Moghoofei
• Mortazavi
• Monavari S

• KMID: 2405069
• DOI: http://doi.org/10.5045/br.2017.52.4.311

Abstract

BACKGROUND
Human parvovirus B19 (B19V) is one of the smallest DNA viruses and shows great resistance to most disinfectants. Therefore, it is one of the common contaminant pathogens present in blood and plasma products. Parvovirus 4 (PARV4) is a newly identified parvovirus, which is also prevalent in parenteral transmission. In this study, we aimed to evaluate the prevalence of B19V and PARV4 DNA among patients with hemophilia in Birjand County in eastern Iran.
METHODS
This was a cross-sectional epidemiological study comprising nearly all people with hemophilia in this region. Whole blood samples were taken after patient registration and sent for plasma isolation. After nucleic acid extraction, B19V was detected with real-time polymerase chain reaction, PARV4 DNA was then detected using sensitive semi-nested PCR.
RESULTS
In total, there were 86 patients with hemophilia, with mean age 28.5±1.5 years. Of these, 90.7% were men and 9.3% women; 84.9% had hemophilia A and 7.0% had hemophilia B. We found 11 patients (12.8%) were positive for B19V DNA and 8 were positive (9.3%) for PARV4 DNA. The prevalence of B19V was higher in middle-aged groups rather than younger people, whereas PARV4 infection was more common in younger patients (P < 0.05).
CONCLUSION
There was a high prevalence of B19V and PARV4 infection in this high-risk group of patients with hemophilia. Due to the clinical significance of the B19 virus, imposing more precautionary measures for serum and blood products is recommended.

Keyword

Parvovirus B19; PARV4; Hemophilia; Prevalence; Iran

MeSH Terms

Disinfectants
DNA
DNA Viruses
Epidemiologic Studies
Female
Hemophilia A*
Hemophilia B
Humans*
Iran
Male
Parvovirus B19, Human*
Parvovirus*
Plasma
Polymerase Chain Reaction
Prevalence
Real-Time Polymerase Chain Reaction
DNA
Disinfectants

Figure

• 

  Fig. 1 Result of PCR for PARV4 produced fragments of 490 base pairs.

Reference

1. Arabzadeh SA, Alizadeh F, Tavakoli A, et al. Human parvovirus B19 in patients with beta thalassemia major from Tehran, Iran. Blood Res. 2017; 52:50–54. PMID: 28401102.

2. Servant A, Laperche S, Lallemand F, et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol. 2002; 76:9124–9134. PMID: 12186896.

3. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev. 2002; 15:485–505. PMID: 12097253.

4. Shabani Z, Esghaei M, Keyvani H, et al. Relation between parvovirus B19 infection and fetal mortality and spontaneous abortion. Med J Islam Repub Iran. 2015; 29:197. PMID: 26157715.

5. Ekman A, Hokynar K, Kakkola L, et al. Biological and immunological relations among human parvovirus B19 genotypes 1 to 3. J Virol. 2007; 81:6927–6935. PMID: 17409158.

6. Soucie JM, Siwak EB, Hooper WC, Evatt BL, Hollinger FB. Universal Data Collection Project Working Group. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. Transfusion. 2004; 44:1179–1185. PMID: 15265122.

7. Mortimer PP, Luban NL, Kelleher JF, Cohen BJ. Transmission of serum parvovirus-like virus by clotting-factor concentrates. Lancet. 1983; 2:482–484. PMID: 6136645.

8. Rubinstein R, Karabus CD, Smuts H, Kolia F, Van Rensburg EJ. Prevalence of human parvovirus B19 and TT virus in a group of young haemophiliacs in South Africa. Haemophilia. 2000; 6:93–97. PMID: 10781195.

9. Röhrer C, Gärtner B, Sauerbrei A, et al. Seroprevalence of parvovirus B19 in the German population. Epidemiol Infect. 2008; 136:1564–1575. PMID: 18198003.

10. Schmidt I, Blümel J, Seitz H, Willkommen H, Löwer J. Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang. 2001; 81:228–235. PMID: 11903998.

11. Kishore J, Misra R, Gupta D, Ayyagari A. Raised IgM antibodies to parvovirus B19 in juvenile rheumatoid arthritis. Indian J Med Res. 1998; 107:15–18. PMID: 9529776.

12. Soucie JM, De Staercke C, Monahan PE, et al. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. Transfusion. 2013; 53:1217–1225. PMID: 22998193.

13. Zakrzewska K, Azzi A, De Biasi E, et al. Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis. J Med Virol. 2001; 65:402–407. PMID: 11536251.

14. Jones MS, Kapoor A, Lukashov VV, Simmonds P, Hecht F, Delwart E. New DNA viruses identified in patients with acute viral infection syndrome. J Virol. 2005; 79:8230–8236. PMID: 15956568.

15. Fryer JF, Kapoor A, Minor PD, Delwart E, Baylis SA. Novel parvovirus and related variant in human plasma. Emerg Infect Dis. 2006; 12:151–154. PMID: 16494735.

16. Simmonds P, Douglas J, Bestetti G, et al. A third genotype of the human parvovirus PARV4 in sub-Saharan Africa. J Gen Virol. 2008; 89:2299–2302. PMID: 18753240.

17. Yu X, Wang J, Zhao B, Ghildyal R. PARV4 co-infection is associated with disease progression in HBV patients in Shanghai. J Med Diagn Methods. 2015; 4:2.

18. Lurcharchaiwong W, Chieochansin T, Payungporn S, Theamboonlers A, Poovorawan Y. Parvovirus 4 (PARV4) in serum of intravenous drug users and blood donors. Infection. 2008; 36:488–491. PMID: 18759058.

19. Benjamin LA, Lewthwaite P, Vasanthapuram R, et al. Human parvovirus 4 as potential cause of encephalitis in children, India. Emerg Infect Dis. 2011; 17:1484–1487. PMID: 21801629.

20. Toppinen M, Norja P, Aaltonen LM, et al. A new quantitative PCR for human parvovirus B19 genotypes. J Virol Methods. 2015; 218:40–45. PMID: 25794796.

21. Tuke PW, Parry RP, Appleton H. Parvovirus PARV4 visualization and detection. J Gen Virol. 2010; 91:541–544. PMID: 19846677.

22. Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis. 2012; 7:24. PMID: 22551339.

23. Marano G, Vaglio S, Pupella S, et al. Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements. Blood Transfus. 2015; 13:184–196. PMID: 25849894.

24. Simmons R, Sharp C, McClure CP, et al. Parvovirus 4 infection and clinical outcome in high-risk populations. J Infect Dis. 2012; 205:1816–1820. PMID: 22492853.

25. Slavov SN, Kashima S, Rocha-Junior MC, et al. Frequent human parvovirus B19 DNA occurrence and high seroprevalence in haemophilic patients from a non-metropolitan blood centre, Brazil. Transfus Med. 2014; 24:130–132. PMID: 24684574.

26. Nishida Y, Arai M, Yamamoto Y, Fukutake K. Serological and virological markers of human parvovirus B19 infection in patients with haemophilia. Haemophilia. 1997; 3:137–142. PMID: 27214724.

27. Shooshtari MM, Foroghi MN, Hamkar R. High prevalence of parvovirus B19 IgG antibody among hemophilia patients in center for special diseases, Shiraz, Iran. Iran J Public Health. 2005; 34:51–54.

28. Sharp CP, Lail A, Donfield S, et al. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis. 2009; 200:1119–1125. PMID: 19691429.

29. Sharp CP, Lail A, Donfield S, Gomperts ED, Simmonds P. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion. 2012; 52:1482–1489. PMID: 22043925.